Abstract Understanding the intermediate-and long-term psychological consequences of genetic testing for cancer patients has led to encouraging research, but a clear consensus of the psychosocial impact and clinical routine for cancer-affected BRCA1 and BRCA2 mutation carriers is still missing. We performed a systematic review of intermediate-and long-term studies investigating the psychological impact like psychological distress, anxiety, and depression in cancer-affected BRCA mutation carriers compared to unaffected mutation carriers. This review included the screening of 1243 studies. Eight intermediate-and long-term studies focusing on distress, anxiety, and depression symptoms among cancer-affected mutation carriers at least six months after the disclosure of genetic testing results were included. Studies reported a great variety of designs, methods, and patient outcomes. We found evidence indicating that cancer-affected mutation carriers experienced a negative effect in relation to psychological well-being in terms of an increase in symptoms of distress, anxiety, and depression in the first months after test disclosure. In the intermediate-and long-term, no significant clinical relevant symptoms occurred. However, none of the included studies used specific measurements, which can clearly identify psychological burdens of cancer-affected mutation carriers. We concluded that current wellimplemented distress screening instruments are not sufficient for precisely identifying the psychological burden of genetic testing. Therefore, future studies should implement coping strategies, specific personality structures, the impact of genetic testing, supportive care needs and disease management behaviour to clearly screen for the possible intermediate-and long-term psychological impact of a positive test disclosure.
Introduction
The detection of mutations in the genes BRCA1 and BRCA2 is a significant advancement in cancer care (Miki et al. 1994; Wooster et al. 1995) . A mutation in these tumor-suppressing genes disposes a patient to an earlier appearance of breast and/or ovarian cancer and an increased lifetime prevalence of developing those and other associated cancer entities. Patients with a mutation of the BRCA1 or BRCA2 gene have an elevated lifetime risk for breast cancer (55 % to 85 %) and ovarian cancer (16 to 60 %) (Easton et al. 1995; Ford et al. 1994; Struewing et al. 1997 ). About 5-10 % of all breast and ovarian cancers are caused by mutations in these high risk genes (Easton et al. 1993; Newman et al. 1988) . Thus, the discovery of susceptible genes for breast and/or ovarian cancer has opened a new field to individualize medicine and an expanded approach for genetic testing in the last few years. According to international cancer guidelines, genetic testing is recommended for women with a strong family history of early disease occurrence at a young age. Generally, BRCA1 and BRCA2 mutation carriers are offered an expanded surveillance program, including clinical examination, ultrasound, mammography and MRI scan in order to detect an early onset of disease; alternatively, they are offered prophylactic surgery (Hampel et al. 2014) .
The diagnosis of cancer and its treatment can lead to a high level of cancer-related distress (Linden et al. 2012; Voorwinden and Jaspers 2015) or clinically relevant symptoms of different mental disorders like depression, anxiety or adjustment disorder (Mehnert et al. 2014; Walker et al. 2014) . The understanding of the psychological consequences of genetic testing for cancer patients has stimulated encouraging research. The psychological impact of genetic testing has been shown to be mediated by the experience of a previous cancer diagnosis and cancer worries (Meiser 2005) . Being a BRCA1 or BRCA2 mutation carrier means living with a lifelong risk of developing cancer (Bonadona et al. 2002) . Cancer-affected women who undergo the process of genetic testing are especially confronted with breast cancer-related fear and show an elevated level of vulnerability (Vansenne et al. 2009 ). This knowledge can increase additional distress as well as anxiety and depressive symptoms throughout their lifetime ). Generally, after a positive test diagnosis the mutation carriers are forced to make treatment decisions like regular surveillance, prophylactic surgery or preventive chemotherapy and can experience the anguish of informing their relatives about the test results (Douglas et al. 2009; MacDonald et al. 2010; van Oostrom et al. 2003) . The impact of this burden has been evaluated in various studies, but the findings have been inconsistent. On the one hand, cancer-affected mutation carriers experienced no significant additional distress. According to these findings, procedures of genetic counselling and testing have no relevant negative impact on the psychological wellbeing of cancer-affected mutation carriers in a shortterm outcome (Reichelt et al. 2004; Schmid-Büchi et al. 2008; Zilliacus et al. 2012) . On the other hand, further research has shown different findings in this patient group. In two other studies, receiving a disclosure of genetic test results and the clear knowledge of being a positive carrier led to additional anxiety, isolation, distress and symptoms of depression over time among cancer-affected mutation carriers (Ardern-jones et al. 2005; Schlich-Bakker et al. 2008 ). Related to these findings, it seems that the knowledge of being a positive carrier causes no clear or clinically relevant psychological impact, like depression or an anxiety disorder; however, cancer-affected mutation carriers expressed a need for support in handling the test results and, beyond that, benefit from psychosocial interventions (Farrelly et al. 2013; van Oostrom et al. 2003; Vos et al. 2013a, b) . Due to the currently inconclusive data a clinical routine and pathway for psychological support is not implicated for a patient undergoing genetic testing (Vos et al. 2013a, b) . However, it is not clear how the knowledge of being a mutation carrier affected intermediate-and long-term psychological well-being, especially for the group of women who were cancer-affected before undergoing genetic testing. Further reviews did not find a psychological impact related to genetic testing especially on the short-term level. However, all authors highlight the lack of outcome data that consider the intermediate-and long-term psychological burden on mutation carriers with a prior cancer diagnosis Hilgart et al. 2012; Nelson et al. 2014; Schlich-Bakker et al. 2006; Vansenne et al. 2009 ).
Therefore, the aim of this systematic review is to summarize the current existing evidence on the effects of genetic testing for BRCA1/2 on psychological burden (psychological distress, anxiety, depression) of canceraffected mutation carriers in intermediate-and longterm prospective and retrospective studies.
Methods

Systematic Literature Search
For data collection, reporting, and discussion we used the guidelines of the PRISMA-Statement Moher et al. 2009 . The search strategies were based on the keywords in a heading or in the text. We also performed a hand search of the reference list among all identified publications for other relevant studies to ensure that all relevant studies for this review were included.
Eligibility Criteria
Studies were eligible for inclusion if they were written in English or German and were published in a peerreviewed journal. For a structured approach for framing our research question we assessed the eligibility of search results according to modified PICOS-criteria Exclusion criteria were studies reporting only medical and somatic parameters (e.g., DNA sequencing, surgery options), medical treatment consequences, screening recommendations, prevalence of mutations in breast cancer patients, or based on pre-symptomatic DNA testing. Literature reviews, case reports, or letters to the editor were excluded. Diseases other than breast and/or ovarian cancer and other hereditary cancer syndromes not related to the BRCA genes were not taken into account.
Study Selection and Data Collection
The first two authors of this paper independently screened the article titles and abstracts of the papers with respect to eligibility. Inter-rater reliability of both independent processes was moderate, with a Cohen's Kappa of 0.54. Afterwards, the two authors discussed inclusion of possible articles. Full texts of potentially relevant studies were independently assessed in regard to the PICOS criteria ; Box 2). The included studies were analyzed with respect to date, country of publication, design, characteristics of study population, measurements, and results. The study groups were analyzed by size, percentage of BRCA1/2 mutation carriers, cancer-affected status, mean age of participants, and psychological outcomes since receipt of genetic test result. We focused specifically on psychological distress, depression, and anxiety. Current and well carried out studies showed high frequencies of distress, anxiety, and depression among breast cancer patients (Linden et al. 2012; Mehnert et al. 2014; Walker et al. 2014) . Therefore, the review focusses on psychological outcomes (distress, anxiety, and depression) that evaluated the intermediate-and long-term psychological impact of a positive BRCA1/2 mutation status on cancer-affected women.
Results
A total of 1243 studies were screened for eligibility. Fifty-nine articles were identified as duplicates and 1102 did not meet the criteria of eligibility. Inspection of abstracts resulted in 82 potentially eligible studies (see Flowchart).
Full text inspection resulted in eight studies focusing on the intermediate-and long-term psychological impact of an identified BRCA mutation among cancer-affected women. The included studies were published between 2002 and 2012. Five studies included participants from the United States. The others were performed in Spain, the Netherlands and Belgium.
Design of Included Studies
All studies can be classified according to intermediate-and long-term psychological outcomes in retrospective studies and follow-up analyses (Table 1) . Four studies had a followup design that reported at least two follow-up assessments after genetic test disclosure. Overall, the mean time of follow-up assessments was 20 months after genetic test disclosure. The other four studies focused on the psychological outcomes at least six months after receiving genetic results.
Study Populations of Included Studies
The study populations of the included studies showed a considerable heterogeneity. Sample size in the reviewed studies 
Eligibility
Studies included n= 8 Included
Full-text articles assessed for eligibility n= 82
Full text articles excluded for reasons n= 74 no relevant outcomes n= 21 wrong sample n= 16 review n= 8 no group comparison n= 7 no long-term outcome n= 7 no experimental study n= 6 not cancer-affected n= 4 duplicate n= 2 language n= 2 letter to the Editor n= 1
varied from 62 to 464 participants (mean n = 217). In total, the included studies produced a sample of 1733 participants. Only one study included male patients with breast cancer as participants. The mean age of the patients varied between 43.2 and 54.2 years with a range of 18 to 89 years in the eight included papers. Taken together, the mean age of the overall sample was 49.4 years. 1156 participants were either affected by breast cancer (n = 609) or by ovarian cancer (n = 25). 8 women were affected by both tumor entities. In 514 participants the cancer diagnosis was not clearly differentiated between breast and ovarian cancer. The sample consisted of 516 BRCA positive and 466 BRCA true negative patients. 751 patients had an inconclusive BRCA status, which is a negative result in the absence of a BRCA gene mutation within the family. None of the studies differentiated between a BRCA1 or BRCA2 gene mutation. The reviewed sample has known about their genetic test disclosure for about 20.8 months (range 6 months to 5 years). Only one study noted the mean time of cancer diagnosis and receiving the genetic test disclosure as being 10.6 years. The other seven reviewed studies did not specify the time between the last cancer diagnosis and genetic counselling ( Table 2 ). The identified studies reported various characteristics for the study group and control group designs. Two studies compared cancer-affected and unaffected patients with a positive or negative gene status (Graves et al. 2012; Smith et al. 2008) . Four studies considered groups with and without a BRCA1/2 mutation; each group included canceraffected and unaffected patients (Beran et al. 2008; Bosch et al. 2012; Halbert et al. 2011; van Dijk et al. 2006) . Two studies compared cancer-affected women according to the BRCA1/2 status (Claes et al. 2004; Schwartz et al. 2002) . We reported in detail the analyzed outcomes regarding to the groups characteristics (Table 2) .
Outcome Measures of Included Studies
Psychological outcome dimensions can be grouped into three categories: (1) distress, (2) anxiety, and (3) depression. The Impact of Event Scale (Beran et al. 2008; Claes et al. 2004; Graves et al. 2012; Schwartz et al. 2002; Smith et al. 2008; van Dijk et al. 2006) , Symptom Checklist 90 Revised (Smith et al. 2008) , Multidimensional Impact of Cancer Risk Assessment (Graves et al. 2012; Halbert et al. 2011) , and Perceived Stress Scale (Graves et al. 2012; Smith et al. 2008 ) were used to identify distress symptoms. Depression was measured with the Hospital Anxiety and Depression Scale (Bosch et al. 2012) , Center of Epidemiologic Studies-Depression Scale (Beran et al. 2008; Smith et al. 2008) , Symptom Checklist 90 (Claes et al. 2004) , Hopkins Symptom Checklist (Schwartz et al. 2002) , and Positive and Negative Affect Scale (Beran et al. 2008 ). The Hospital Anxiety and Depression Scale (Bosch et al. 2012 ), State-Trait Anxiety Inventory (Beran et al. 2008; Claes et al. 2004 ; Smith (Schwartz et al. 2002) evaluated anxiety symptoms. Due to considerable heterogeneity in the population and the measures used, it was not possible to perform a meta-analysis. Therefore, we present the main psychological findings of the considered articles narrative in summary form.
Distress
Seven of the included studies reported distress among canceraffected women with a carrier status (Table 3 ) (Beran et al. 2008; Claes et al. 2004; Graves et al. 2012; Halbert et al. 2011; Schwartz et al. 2002; Smith et al. 2008; van Dijk et al. 2006 ). In the first six months a higher distress level for mutation carriers compared to non-mutation carriers was found in all studies (Beran et al. 2008; Claes et al. 2004; Graves et al. 2012; Halbert et al. 2011; Schwartz et al. 2002; Smith et al. 2008; van Dijk et al. 2006 ). In addition, cancer-affected mutation carriers still suffered from increased distress symptoms compared to non-carriers, as well as to unaffected mutation carriers in follow-up assessment. Beran et al. (Beran et al. 2008) found this effect after 6 months, Claes et al. at a median of 17 months (Claes et al. 2004) , and Graves et al. after five years respectively (Graves et al. 2012 ). Higher levels of distress were measured in breast cancer patients as compared to ovarian cancer patients by Claes et al. (Claes et al. 2004 ). However, the overall distress levels did not reach a clinically relevant level in cancer-affected mutation carriers. Experiencing distress was although associated with the time passed from test disclosure, having had one's ovaries removed and younger age (Halbert et al. 2011) . Prophylactic risk reducing surgery did not decrease the levels of distress among mutation carriers (Graves et al. 2012) . In contrast, two papers described a decrease in distress level in cancer-affected mutation carriers after six months (Schwartz et al. 2002; Smith et al. 2008 ). Other authors found no significant effect of a prior cancer status on distress level among mutation carriers (Halbert et al. 2011; Schwartz et al. 2002; van Dijk et al. 2006 ). Halbert et al. highlighted that unaffected mutation carriers experienced significantly higher distress compared to mutation carriers with a personal cancer history (Halbert et al. 2011 ) and van Dijk and colleagues found an increase of distress in cancer-unaffected mutation carriers overtime (van Dijk et al. 2006 ).
Anxiety and Depression
Separating anxiety and depression outcomes was not possible due to not being differentiated by the included studies. Five studies assessed the effect of BRCA mutation on anxiety and depression outcomes among cancer-affected mutation carriers as compared to cancer-unaffected mutation carriers or canceraffected women with a negative BRCA status (Table 3 ) (Beran et al. 2008; Bosch et al. 2012; Claes et al. 2004; Schwartz et al. 2002; Smith et al. 2008) . Two studies identified increased anxiety and/or depression scores in mutation carriers irrespective of a cancer diagnosis (Claes et al. 2004; Smith et al. 2008) . After three months, anxiety was significantly higher in the cancer-affected mutation carrier subgroup compared to the cancer-unaffected mutation carrier subgroup. (Bosch et al. 2012) . After six months Beran et al. found a higher anxiety score in cancer-affected mutation carriers and a clinically relevant depression score among mutation carriers compared to non-carriers (Beran et al. 2008 ). Smith et al. showed that a high distress level moderates the anxiety outcome among mutations carriers (Smith et al. 2008) . Further cancer diagnosis moderated the impact of anxiety and depression in two studies by mutation carriers (Beran et al. 2008; Bosch et al. 2012) . Clinical relevant anxiety and depression scores at baseline were related to clinical relevant scores after one year of a positive or negative test disclosure (Bosch et al. 2012) . Schwartz et al. and Beran et al. reported that anxiety and depression symptoms decreased after six months (Schwartz et al. 2002) and 12 months (Beran et al. 2008 ). Both studies reported that a positive BRCA status had no intermediate-or long-term effect on psychological wellbeing in cancer-affected patients (Beran et al. 2008; Schwartz et al. 2002) .
No Reported Risk Factors of Poor Well-Being
None of the studies focused on possible risk factors or trait factors that might influence distress, anxiety, or depression after genetic testing. Only two studies mentioned that a prior cancer diagnosis or a pre-existing clinically relevant anxiety or depression score could lead to relevant psychopathological distress among cancer-affected women with BRCA positive status (Beran et al. 2008; Bosch et al. 2012) .
Discussion Summary of the Results
To our knowledge, this was the first systematic review to focus on the intermediate-and long-term psychological burden of positive gene status in cancer-affected women. We found eight studies that investigated psychological outcomes among women who were affected by cancer and who were mutation carriers. All in all, a positive BRCA gene status seemed to result -at least in the first twelve months -in a negative effect on the psychological well-being in terms of increased distress, symptoms of depression, and anxiety. Two studies even showed considerable psychological distress in cancer-affected mutations carriers, which still existed after four and five years (Graves et al. 2012; Halbert et al. 2011 ). In Positive and Negative Affect Scale State-Trait Anxiety Inventory For the first six months a higher level of distress was found after test disclosure in the experimental group compared to the control group. However, 6 months after genetic test disclosure Ca (+) and UnCa (+), as compared to Ca (−) and UnCa (−), suffered more often from clinically relevant depressive symptoms and a higher anxiety score. Overall, the reactions of Ca (+) differ, but not significantly compared to UnCa (+). After 12 months all symptoms returned to baseline levels, which existed before genetic test disclosure and neither group differed in their outcomes.
van Dijk et al. (2006, Netherlands) Exploration of the course of distress and cancer-specific anguish for cancer affected women after 2 weeks of counseling, 1 and 7 months after a genetic test disclosure.
Analyzed sample = 235 Mean age = not reported Experimental Group:
Ca(+) = 20 UnCa (+) = 22
Impact of Event Scale Significant group differences were observed in worry and distress levels over time. Ca (+) and UnCa (+) had the highest distress and cancer related anguish scores compared to Ca (/), UnCa (−), and UnCa (/). UnCa (−) had a linear decrease in distress over time and the lowest score overall compared to the other subgroups. The mean level of Ca (−) = 7 Ca (/) = 36
Impact of Event Scale Symptom Checklist
State -Trait Anxiety Inventory Ca (+) experienced higher levels of distress over time as compared to the Ca (−) and Ca (/) groups, but none of these levels were clinically meaningful or significant. Higher depression and anxiety scores were not reported by Ca (+). Within the group comparison breast cancer women experienced significantly higher levels of distress than women affected by ovarian cancer. Overall, high levels of anxiety and depression were found in 23 % and 30 % of all participants, but there were no specific differences in the cancer subgroups. 
Impact of Event Scale Hopkins Symptom Checklist Ca (+) and Ca (/) did not differ in the baseline measurements of distress, anxiety, and depression. However, after six months no changes in the psychological outcomes were found; in comparison to the baseline a decrease in distress and psychological symptoms was measured in cancer-affected mutation carriers as well as in cancer-affected non-mutation carriers after six months.
contrast, two studies reported a decrease of distress symptoms even to the baseline after six and twelve months (Schwartz et al. 2002; Smith et al. 2008) . A potential clinically relevant depression and higher anxiety symptoms were found in cancer-affected mutation carriers in two studies (Beran et al. 2008; Bosch et al. 2012) . However, other studies in this review showed that a positive BRCA genetic test disclosure among cancer-affected women did not lead to a higher prevalence of depression or an anxiety disorder compared to unaffected mutations carriers (Claes et al. 2004; Schwartz et al. 2002; Smith et al. 2008) . As hypothesized, a prior breast and/or ovarian cancer diagnosis predicted higher distress, depression, and anxiety scores in cancer-affected mutation carriers after three months, twelve months, at a median of 17 months and on average of 5 years (Beran et al. 2008; Bosch et al. 2012; Claes et al. 2004; Graves et al. 2012 ). Others did not find this effect in their study population (Halbert et al. 2011; Schwartz et al. 2002; van Dijk et al. 2006) . Our contradictory findings of intermediate-and long-term effects are similar to those reported by other reviews focusing on the short-term effects of genetic testing on cancer-affected patients (Heshka et al. 2008; Schlich-Bakker et al. 2006; Vansenne et al. 2009 ).
Findings are Contradictory
One possible explanation for contradictory findings is that genetic testing may be perceived as a benefit for the psychological well-being of some cancer patients. It seems that the well-defined medical treatment protocol and surveillance for mutation carriers make the treatment processes predictable and understandable. Due to this, mutation carriers reported more positive lifetime changes and were better able to handle the situation than if there were uncertainty (Brunstrom et al. 2015; Low et al. 2008) . However, this finding should be interpreted carefully. The validity of self-reported benefit is often criticized in the literature (Low et al. 2008) . Furthermore, another explanation for the contradictory findings is the diverse measurements, which were used to measure the psychological impact of genetic testing and positive BRCA gene status. Overall, well-implemented distress measurements are used to screen posttraumatic distress or psychopathological symptoms like depression and anxiety e.g., the Impact of Event Scale. None of these measurements screen the specific distress of a positive BRCA hereditary carrier status. Depending on the psychological measurements used the number of burdened patients varies. Vos et al. showed that the genetic-specific distress measurements could better predict the self-reported need for counselling compared to psychopathology distress outcomes (Vos et al. 2013a, b) . Recently, the Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire has been developed and published. The PAHC questionnaire can be used as a first-line screener for psychosocial burden among cancer-affected patients who undergo the process of genetic testing (Eijzenga et al. 2014a, b; Eijzenga et al. 2014a, b) . A further possible explanation for the contradictory findings in this field is the complex interaction of personal trait parameters. These trait variables inherently influence psychological well-being. Therefore, distress is not only influenced by gene status but also by gender, illness history, demographic, or psychological variables (Croyle et al. 1997; Cukier et al. 2013; van der Meer et al. 2015) . Tercyak et al. also showed that the distress level after receiving a genetic test result also depends on the coping style and not just on the positive or negative gene status (Tercyak et al. 2001) . However, the experience of a prior cancer diagnosis can enhance the coping abilities of mutation carriers (Hallowell et al. 2004; Meiser 2005) . For this reason, cancer-affected mutation carriers may not suffer from higher levels of distress or other psychological symptoms. The results were even comparable to non-affected women or non-mutation carriers. Still it is not clear if this effect is stable in intermediate-and long-term studies and future studies are needed for clarification. It is important to concentrate on psychological outcomes in further studies because it has been shown that some patients suffer under psychological burden and some do not after genetic testing. Additionally, previous studies showed that psychological outcomes influenced the decision making process; e.g., individualized cancer-risk-reduction strategies, chemo prevention, communication in the family, and quality of life (Carpenter et al. 2013; Christinat and Pagani 2013; Crotser and Boehmke 2009; Hallowell et al. 2002) .
Limitations of the Included Studies and Further Consideration
First, the risk of a publication bias exists in our review because we only screened studies which were published in peer-reviewed journals. Second, the great variety of measurements, and therefore limited comparability, is a major restraint of the included studies. The studies we analyzed included different standardized measures concerning anxiety, depression, and cancer-specific distress. Furthermore, none of the studies measured important personality outcomes like coping behavior, supportive care needs, family functioning, disease management behavior or psychosocial aspects of hereditary cancer with valid coping questionnaires (e.g., Mini-Mental Adjustment to Cancer scale (Watson et al. 1994) ; PAHC questionnaire (Eijzenga et al. 2014a, b) ). These psychological outcomes may be valuable to clearly screen the possible intermediate-and long-term impact of a positive mutation status among cancer-affected women because the psychological responses to the notification of one's test disclosure are presently contradictory. Third, several hypotheses, testing time, heterogeneity of study populations, or size impeded study selection. In addition, studies related to the BRCA1/2 tumor syndromes are of limited number. Often they included only a small number of patients, inconsistent group size, and evaluated the overall psychological impact, as well as other outcomes like decision-making, impact of specific surveillance examinations, or risk perception, in different patient groups. The impact of clear psychological aspects of being a cancer patient with a high risk of developing another malignant tumor was not comprehensively considered. One of the most problematic issues of current studies is the unclear grouping of patients in experimental and control groups. Several studies classified affected and unaffected mutation carriers in one group, disregarding that a prior diagnosis of cancer may significantly influence the psychological outcome. All studies included only Caucasians women who were welleducated had high incomes, and had good access to healthcare. Hence, intermediate-and long-term psychological impact also depends on the insurance system, access to the medical system, surveillance options, income, and cultural aspects (Cukier et al. 2013; de Souza et al. 2014) this should be considered in future studies.
Conclusion and Clinical Implication
The current review is, to the best of our knowledge, the first to specifically examine studies of intermediate-and long-term psychological outcomes of cancer-affected mutation carriers in a rigorous way using systematic and replicable methodology. Overall, the findings of the eight included studies implicated that cancer-affected BRCA mutation carriers experience distress in the first twelve months after genetic testing, but do not experience clinically meaningful anxious or depressive symptoms in the intermediate-and long-term level. However, comparison of the different studies was limited due to a great variety in study methods and design. More definitive groups, individuals from different social origins, and non-Caucasian participants in intermediate-and long-term designs are needed to get a better idea of the psychological burden on these patients. Furthermore, it is absolutely essential to examine psychological outcomes like family function, risk factors, unmet needs, mutation carrier's worries and coping strategies, and specific personality structures to predict the intermediate-and long-term psychological impact (Crotser and Boehmke 2009; Tercyak et al. 2001; van der Meer et al. 2015) . Well-implemented distress screening instruments are not sufficient for precisely identifying the psychological burden of genetic testing (Vos et al. 2013a, b) . However, specific screening instruments like the PAHC questionnaire seem to be promising (Eijzenga et al. 2014a, b) . Consideration of coping strategies, the impact of genetic testing or disease management behaviour should be implemented in clinical practice to clearly screen for the possible intermediate-and long-term impact of a positive test disclosure status. This approach is urgently required in psycho-oncology care in order to offer genetic tested cancer patients psychosocially adequate support in time when indicated.
